Clinical trials: Diabetic Kidney Disease
Diabetes, Hypertension
Renal and Hormonal Effects of Pioglitazone
This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects.
- Trial name
- NCT01090752
- Testing
- Pioglitazone, Metformin
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University Hospital, Geneva
Chronic Kidney Disease
Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Patients with type 2 diabetes, obesity, and chronic kidney disease are generally physically inactive, have a high mortality rate, and may benefit from an exercise program.
- Trial name
- EX-ODCKD (NCT01036490)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetic Nephropathy
Renoprotection in Early Diabetic Nephropathy in Pima Indians
This investigation is a randomized, double-blinded, placebo-controlled clinical trial in adult diabetic Pima Indians with normal urinary albumin excretion (albumin-to-creatinine ration less than 30 mg/g) or microalbuminuria…
- Trial name
- NCT00340678
- Testing
- Losartan
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Diabetic Kidney Disease
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
The primary objective of this study is to determine the effect of selonsertib (formerly GS-4997) on estimated glomerular filtration rate (eGFR) decline in participants with diabetic kidney disease (DKD).
- Trial name
- NCT02177786
- Testing
- Selonsertib
- Where
- 105 sites in United States, Canada
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
- Trial name
- MOSAIC (NCT04026165)
- Testing
- SEL
- Where
- 111 sites in United States, Australia and 3 more
- Volunteers
- 384 people
- Sponsor
- Gilead Sciences
End Stage Renal Disease (ESRD), Diabetes
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients…
- Conditions
- End Stage Renal Disease (ESRD), Diabetes, CAPD
- Trial name
- EDEN (NCT01219959)
- Testing
- Dianeal, Dianeal, Extraneal, Nutrineal
- Where
- 16 sites in Colombia
- Volunteers
- 71 people
- Sponsor
- Vantive Health LLC
Diabetic Peripheral Neuropathic Pain, Post-herpetic Neuralgia
DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
Investigate the safety and efficacy of DS-5565 in Japanese subjects with Diabetic Peripheral Neuropathic Pain (DPNP) with renal impairment or Post-Herpetic Neuralgia (PHN) with renal impairment.
- Trial name
- NCT02607280
- Testing
- DS-5565
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Anemia
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy.
- Trial name
- NCT00354341
- Testing
- Epoetin beta
- Where
- 63 sites in Austria, Brazil and 15 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Diabetic Kidney Disease
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure.
- Trial name
- NCT01847313
- Testing
- Liraglutide
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Karl Neff
Diabetes
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
The study aims to investigate the clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease (CVD), chronic kidney disease (CKD)…
- Trial name
- NCT04903496
- Where
- China
- Volunteers
- 1,233,162 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Heart Failure, Type 2 Diabetes Mellitus
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild…
- Trial name
- RECEDE-CHF (NCT03226457)
- Testing
- Empagliflozin 25mg, Frusemide
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Dundee
Kidney Transplant, Diabetes Mellitus, Type 2
Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Protocol Title: Randomized open label study comparing the metabolic control of first Kidney Transplant recipients with Type 2 Diabetes Mellitus (DM) receiving either Prograf or Neoral as part of a ATG induction, prednisone free…
- Conditions
- Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
- Trial name
- NCT00296296
- Testing
- Cyclosporin, Tacrolimus, 'Diabetes Education / Management'
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Stanford University
Diabetes Mellitus, Diet
LoBAG30 Diet in Patients on Metformin
We will determine the metabolic response to a Low Biologically Available Glucose Diet (LoBAG30) in subjects currently receiving the maximum dose of metformin as monotherapy in whom the glycohemoglobin is not at an acceptable…
- Trial name
- LoBAG Diet (NCT00607867)
- Testing
- LoBAG30 diet, Control Diet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- US Department of Veterans Affairs